Drugs were well tolerated and the treatment significantly decreased tumor‐infiltrating CD14+ monocytes, which are associated with tumor progression and metastatic disease, and reduced markers of epithelial‐to‐mesenchymal transition (EMT), reducing the pro‐metastatic capacity of the malignant tissue. The gene discussed is CD14; the disease is metastatic neoplasm.